Abstract Library

#2072 Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study

Introduction: Gastroenteropancreatic (GEP) grade 3 neuroendocrine neoplasms (NEN G3) are rare, highly malignant neoplasms with poor prognosis and limited therapeutic options. Median survival following chemotherapy is only 10-12 months.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Skovgaard D

Authors: Skovgaard D, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H,

Keywords: neuroendocrine neoplasms, WHO grade 3, PRRT, Progression-free survival, Overall survival,

#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors

Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Braat A

Authors: Braat A, Kappadath C, Ahmadzadehfar H, Stothers C, Deroose C,

Keywords: PRRT, Radioembolization, neuroendocrine tumors, metastasis, radionuclide treatments,